Clinical Trial Update: AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing AZD9291 (osimertinib) to gefitinib or erlotinib in locally advanced or metastatic EGFR-sensitizing mutation positive non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)
• TAGRISSO (osimertinib)
• Tarceva (erlotinib)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-11-06